Role of regucalcin expression in liver tissue: systematic review
DOI:
https://doi.org/10.19230/jonnpr.4066Keywords:
Apoptosis; hepatocellular carcinoma; HepG2 cells; biochemical markers; RGN; SMP30Abstract
Objective. The purpose of this work has been to review the scientific literature regarding the role of regucalcin expression in the liver.
Method. A bibliographic search was carried out on the PubMed database. Eighty-nine articles were found. After analyzing their content and applying inclusion and exclusion criteria, a total of 9 articles were included.
Results. It was determined that SMP30 expression is significantly higher in the liver compared to other tissues such as lungs, spleen, myocardium, prostate and skin (P < 0.05). It was observed, after obtaining samples from 137 patients (30 normal liver controls, 10 with hepatitis B, 49 with liver cirrhosis and 48 with hepatocellular carcinoma) that SMP30 expression was 100% in all tissues adjacent to the liver except for hepatocellular carcinoma (HCC), which showed only 81% of protein expression. On serum regucalcin concentrations it was observed, that 3 different groups with different concentrations of SMP30: control group (1.72 ng/ mL), patients with chronic hepatitis (3.76 ng/mL) and patients with liver failure (5.46 ng/ mL) patients with acute liver failure had higher concentrations of SMP30 than patients with hepatitis B (P< 0.01), as well as the serum concentrations of the latter showed to be higher than in healthy patients (P< 0.01). On the proliferation of HepG2 cells it has been shown that the addition of exogenous SMP30 suppresses the elevation of cell numbers, thus revealing that HepG2 cell proliferation was suppressed with the physiological levels of SMP30 present in serum in vitro.
Conclusion. Regucalcin could play a key role in survival in patients with hepatocellular carcinoma, as well as its possible role as a protective protein for apoptosis in HepG2 cells.
Downloads
References
Yamaguchi M, Yamamoto T. Purification of Calcium Binding Substance from Soluble Fraction of Normal Rat Liver. Chem Pharm Bull (Tokyo). 1978;26(6):1915-8.
Yamaguchi M. A novel Ca^<2+>-binding protein regucalcin and calcium inhibition: regulatory role in liver cell function. Calcium Inhib. 1992;19-41.
Yamaguchi M. Role of calcium-binding protein regucalcin in regenerating rat liver. J Gastroenterol Hepatol. 1998;13(S1):S106-12.
Yamaguchi M. Role of regucalcin in calcium signaling. Life Sci. 31 de marzo de 2000;66(19):1769-80.
Yamaguchi M. The Role of Regucalcin in Nuclear Regulation of Regenerating Liver. Biochem Biophys Res Commun. 16 de septiembre de 2000;276(1):1-6.
Shimokawa N, Yamaguchi M. Calcium administration stimulates the expression of calcium-binding protein regucalcin mRNA in rat liver. FEBS Lett. 1992;305(2):151-4.
Yamaguchi M, Nakajima R. Role of regucalcin as an activator of sarcoplasmic reticulum Ca2+-ATPase activity in rat heart muscle. J Cell Biochem. 2002;86(1):184-93.
Yamaguchi M, Isogai M, Kato S, Mori S. Immunohistochemical Demonstration of Calcium-Binding Protein Regucalcin in the Tissues of Rats : The protein Localizes in Liver and Brain. Chem Pharm Bull (Tokyo). 1991;39(6):1601-3.
Yamaguchi M. Suppressive role of regucalcin in liver cell proliferation: involvement in carcinogenesis. Cell Prolif. 22 de mayo de 2013;46(3):243-53.
Thiselton DL, McDowall J, Brandau O, Ramser J, d’Esposito F, Bhattacharya SS, et al. An Integrated, Functionally Annotated Gene Map of the DXS8026–ELK1 Interval on Human Xp11.3–Xp11.23: Potential Hotspot for Neurogenetic Disorders. Genomics. 1 de abril de 2002;79(4):560-72.
Yamaguchi M. Involvement of regucalcin as a suppressor protein in human carcinogenesis: insight into the gene therapy. J Cancer Res Clin Oncol. 1 de agosto de 2015;141(8):1333-41.
Yamaguchi M, Osuka S, Shoji M, Weitzmann MN, Murata T. Survival of lung cancer patients is prolonged with higher regucalcin gene expression: suppressed proliferation of lung adenocarcinoma A549 cells in vitro. Mol Cell Biochem. 1 de junio de 2017;430(1):37-46.
Yamaguchi M, Osuka S, Weitzmann MN, Shoji M, Murata T. Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro. Int J Oncol. agosto de 2016;49(2):812-22.
Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M, Murata T. Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol. 1 de mayo de 2016;48(5):1955-64.
Zheng S-X, Xiang B-D, Long J-M, Qu C, Mo Z-J, Li K, et al. Diagnostic Value of Serum SMP30 and Anti-SMP30 Antibody in Hepatocellular Carcinoma. Lab Med. 5 de julio de 2018;49(3):203-10.
Mo Z, Zheng S, Lv Z, Zhuang Y, Lan X, Wang F, et al. Senescence marker protein 30 (SMP30) serves as a potential prognostic indicator in hepatocellular carcinoma. Sci Rep. diciembre de 2016;6(1):39376.
Zhou S-F, Xie X-X, Bin Y-H, Lan L, Chen F, Luo G-R. Identification of HCC- 22-5 tumor-associated antigen and antibody response in patients. Clin Chim Acta. abril de 2006;366(1-2):274-80.
Kondo Y, Ishigami A. Involvement of senescence marker protein-30 in glucose metabolism disorder and non-alcoholic fatty liver disease. Geriatr Gerontol Int. 2016;16(S1):4-16.
Handa S, Maruyama N, Ishigami A. Over-expression of Senescence Marker Protein-30 Decreases Reactive Oxygen Species in Human Hepatic Carcinoma Hep G2 Cells. Biol Pharm Bull. 2009;32(10):1645-8.
Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M, Murata T. Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. Int J Oncol. 1 de octubre de 2016;49(4):1686-94.
Zhou S-F, Mo F-R, Bin Y-H, Hou G-Q, Xie X-X, Luo G-R. Serum immunoreactivity of SMP30 and its tissues expression in hepatocellular carcinoma. Clin Biochem. 1 de marzo de 2011;44(4):331-6.
Fujita T, Uchida K, Maruyama N. Purification of senescence marker protein-30 (SMP30) and tis androgen-independent decrease with age in the rat liver. Biochim Biophys Acta BBA - Gen Subj. 22 de abril de 1992;1116(2):122-8.
Matsuyama S, Kitamura T, Enomoto N, Fujita T, Ishigami A, Handa S, et al. Senescence marker protein-30 regulates Akt activity and contributes to cell survival in Hep G2 cells. Biochem Biophys Res Commun. 20 de agosto de 2004;321(2):386-90.
Yamaguchi M. Regucalcin as a potential biomarker for metabolic and neuronal diseases. Mol Cell Biochem. 1 de junio de 2014;391(1):157-66.
Yamaguchi M, Isogai M. Tissue concentration of calcium-binding protein regucalcin in rats by enzyme-linked immunoadsorbent assay. Mol Cell Biochem. 1 de mayo de 1993;122(1):65-8.
Wei X, Yu H, Zhao P, Xie L, Li L, Zhang J. Serum regucalcin is a useful indicator of liver injury severity in patients with hepatitis B virus-related liver diseases. Braz J Med Biol Res [Internet]. 30 de septiembre de 2019 [citado 7 de agosto de 2020];52(10). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774222/
Tsurusaki Y, Yamaguchi M. Role of regucalcin in liver nuclear function: Binding of regucalcin to nuclear protein or DNA and modulation of tumor- related gene expression. Int J Mol Med [Internet]. 1 de agosto de 2004 [citado 20 de octubre de 2020]; Disponible en: http://www.spandidos- publications.com/10.3892/ijmm.14.2.277
Yamaguchi M, Sakurai T. Inhibitory effect of calcium-binding protein regucalcin on Ca2+-activated DNA fragmentation in rat liver nuclei. FEBS Lett. 1991;279(2):281-4.
Izumi T, Yamaguchi M. Overexpression of regucalcin suppresses cell death in cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-? or thapsigargin. J Cell Biochem. 15 de mayo de 2004;92(2):296-306.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
